The XelOx regimen is currently quite popular. A Phase III study showed the chemotherapy combination XELOX (Xeloda + oxaliplatin) to be as effective — in terms of progression-free survival (PFS) — as the current standard treatment, FOLFOX-4 (infused 5-FU/leucovorin + oxaliplatin), in the treatment of advanced (metastatic) colorectal cancer. The latest version of the NCCN Colon Cancer Guidelines include several major changes to recommended courses of treatment based on recent relevant clinical studies and changing practice patterns. One significant change is the recommendation of capecitabine (Xeloda) and oxaliplatin (Eloxatin) also known as CAPOX as a treatment option in first-line therapy. Whether Avastin is helpful with this regimen is under study in a phase III trial.
Kocha W, Maroun J, Jonker D, Rumble RB, Zuraw L, Gastrointestinal Cancer Disease Site Group. Oral capecitabine (Xeloda) in the first-line treatment of metastatic colorectal cancer: a clinical practice guideline. Toronto (ON): Cancer Care Ontario (CCO); 2005 Feb 11. 27 p. (Evidence-based series; no. 2-15). [30 references] NCCN.ORG, Golon